A randomized double-blind parallel study of rabeprazole extended-release 50 mg versus esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastroesophageal reflux disease (GERD)

Trial Profile

A randomized double-blind parallel study of rabeprazole extended-release 50 mg versus esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastroesophageal reflux disease (GERD)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Esomeprazole (Primary) ; Rabeprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Inc; Eisai Medical Research
  • Most Recent Events

    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 04 Jul 2012 Additional trial location (Lithuania) identified as reported by EudraCT.
    • 13 Aug 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top